Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 15, 2025, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg".